1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry

Autor: Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Melissa B. Aquino, Petr Hájek, Borislav Atzev, Martin Hudec, Tiong Kiam Ong, Martin Mates, Borislav Borisov, Hazem M. Warda, Peter den Heijer, Jaroslaw Wojcik, Andres Iniguez, Zdeněk Coufal, Ahmed Khashaba, Muhammad Munawar, Robert T. Gerber, Bryan P. Yan, Paula Tejedor, Petr Kala, Houng Bang Liew, Michael Lee, Deborah N. Kalkman, George D. Dangas, Robbert J. de Winter, Antonio Colombo, Roxana Mehran

Publikováno v: International Journal of Cardiology: Heart & Vasculature, Vol 31, Iss , Pp 100605- (2020)

Background: The COMBO stent is a biodegradable-polymer sirolimus-eluting stent with endothelial progenitor cell capture technology for faster endothelialization. Objective: We analyzed COMBO stent outcomes in relation to bleeding risk using the PARIS

Externí odkaz: https://doaj.org/article/e55423582fb44594b38687802ca06541

One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration

Autor: Borislav Atzev, Petr Hájek, Martin Hudec, Pier Woudstra, Melissa Aquino, Zdeněk Coufal, Tiong Kiam Ong, Mascot, Roxana Mehran, Michael S. Lee, Martin Mates, Doreen Zeebregts, Karel T. Koch, Deborah N. Kalkman, Robbert J. de Winter, Peter den Heijer, Antonio Colombo, Hazem M. Warda, Jan G.P. Tijssen, Rishi Chandiramani, Vera C de Winter, Jaya Chandrasekhar, Borislav Borisov, Jarosław Wójcik, Marcel A.M. Beijk, Andrés Iñiguez, Remedee registry investigators, George Dangas, Samantha Sartori, Puk de Wilde, Usman Baber

Publikováno v: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, 35(2), 309-320. Kluwer Academic Publishers

Purpose: The COMBO biodegradable polymer sirolimus-eluting stent includes endothelial progenitor cell capture (EPC) technology for rapid endothelialization, which may offer advantage in acute coronary syndromes (ACS). We sought to analyze the perform

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89720010f55dc2d5f9d1c8130bde5f54
https://doi.org/10.1007/s10557-020-07087-6

1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score–Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents

Publikováno v: JACC. Cardiovascular interventions. 13(7):820-830

Objectives: The aim of this study was to determine 1-year safety and efficacy after treatment with the COMBO and Orsiro stents. Background: The COMBO stainless-steel stent has an anti-CD34+ antibody coating to capture endothelial progenitor cells, th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dris___00893::08287bef2c28aad2a4daee9953991e1a
https://doi.org/10.1016/j.jcin.2019.11.023

One‐year clinical outcomes in patients with chronic kidney disease treated with COMBO stents: From the COMBO collaboration

Autor: Usman Baber, Moritz Blum, Jan G.P. Tijssen, Samantha Sartori, Karel T. Koch, Deborah N. Kalkman, Roxana Mehran, Melissa Aquino, Robbert J. de Winter, Antonio Colombo, Pier Woudstra, Jaya Chandrasekhar, Marcel A.M. Beijk, George Dangas

Publikováno v: Catheterization and Cardiovascular Interventions
Catheterization and Cardiovascular Interventions, Wiley, 2020, ⟨10.1002/ccd.29270⟩
Catheterization and cardiovascular interventions, 98(6), 1095-1101. Wiley-Liss Inc.

International audience; Background: Chronic kidney disease (CKD) patients undergoing percutaneous coronary intervention (PCI) experience greater ischemic events including clinically driven target lesion revascularization (CD-TLR). Whether the COMBO b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5965accfe22c8ae8820ec5a2e3712c3
https://hal.sorbonne-universite.fr/hal-02961217

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.